Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged ≥18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during -, and received idarucizumab or andexanet alfa. The cost of ‘out of date’ stock must not be charged to the CCGs.Īs these drugs are used in the emergency situation, BCCG and LCCG confirmed that the Trusts would not be required to submit proformas for funding approval.Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors. The CCGs will only fund the costs of these products when they are administered to a patient.Commissioning of liothyronine injection for the management of organ donors after brain death is not currently recommended.for the treatment of myxoedema coma, usually in conjunction with other measures including the intravenous injection of a corticosteroid). Liothyronine injection is supported for its licensed indication (i.e.Idarucizumab injection is commissioned (as with other antidotes), in line with Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidotes.As a result of this, the CCGs needed to confirm commissioning arrangements relating to these products.
Idarucizumab Injection and Liothyronine Injection are excluded from the National Tariff.
0 kommentar(er)
